SynthesisBlood cancer journal2025
Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis.
Synthesis in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: a systematic review and meta-analysis.International journal of hematology · 2026Pooled it
- First-Line treatment for transplant-ineligible newly diagnosed multiple myeloma: a Bayesian network meta-analysis of efficacy, safety, and high-risk subgroups.Frontiers in immunology · 2026Pooled it
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frontline therapy for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) has advanced with anti-CD38 monoclonal antibody (mAb)-based regimens. Although quadruplet combinations incorporating daratumumab and isatuximab have demonstrated improved response rates and progression-free survival (PFS), comparative overall survival (OS) data remain limited. We performed a systematic review, network meta-analysis (NMA), and reconstructed individual patient data meta-analysis comparing survival outcomes of quadruplet versus triplet regimens in TI-NDMM. This study adhered to Cochrane and PRISMA guidelines and was registered prospectively (PROSPERO CRD420251033401). A comprehensive literature search through April 2025 identified randomized clinical trials (RCT) evaluating quadruplet and triplet regimens involving daratumumab, isatuximab, bortezomib, lenalidomide, and dexamethasone in any combination, compared to their backbone regimens, reporting OS and PFS. Four RCT (n = 2,038) were included. At 60 months, estimated PFS rates were: D-VRd (66.4%), I-VRd (63.2%), D-Rd (51.9%), and VRd (42.6%). Both D-VRd and I-VRd significantly improved PFS compared with D-Rd (HR 0.65; 95% CI 0.48-0.87; and HR 0.68; 95% CI 0.52-0.89) and VRd (HR 0.51; 95% CI 0.39-0.67; and HR 0.53; 95% CI 0.41-0.67). D-Rd also showed superior PFS over VRd (HR 0.77, 95% CI 0.64-0.93; P = 0.007). At 60 months, OS rates were: D-VRd (72.8%), I-VRd (72.2%), D-Rd (67.1%), and VRd (67.0%). Pooled analyses demonstrated that quadruplets significantly improved both PFS (64.7% vs. 46.3%; HR 0.57, 95% CI 0.47-0.69; P < 0.0001) and OS (72.5% vs. 67.1%; HR 0.78, 95% CI 0.63-0.96; P = 0.02) compared to triplet regimens. The OS benefit of quadruplets was consistent in comparisons against both D-Rd (HR 0.77; 95% CI: 0.60-0.98; P = 0.04) and VRd (HR 0.77; 95% CI: 0.62-0.97; P = 0.02). In the NMA, quadruplet regimens ranked highest for complete response, PFS, and OS. This meta-analysis supports anti-CD38 mAb-based quadruplet regimens as superior frontline therapy in TI-NDMM, significantly improving overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.